At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) summarises the status of poly (ADP-ribose) polymerase (PARP) inhibitors in preclinical and clinical development for the treatment of breast cancer. Prof. Dr. med. Fasching explains the design of the EMBRACA study, which is a 2:1 randomised phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.
This programme is supported by BioMarin Pharmaceutical.
